NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

399.65 1.20 (0.30%)

37.34% Gain from 52W Low

2.0M NSE+BSE Volume

NSE 27 Nov, 2025 3:31 PM (IST)

53,431.8

Market Cap

Market Leader

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

28 Oct 2020, 12:00AM

399.65

0.30%

BIOCON LTD

Buy: Biocon Ltd.

Target

Geojit BNP Paribas

Outlook remains intact on new product launches, strong pipeline and limited competition in Biosimilars. Additionally, demographic changes will help drive demand across products. Hence, we maintain our BUY...

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

26 Oct 2020

399.65

0.30%

Result Update:Biocon

Buy: Biocon Ltd.

Axis Direct

Biocon' Q2FY21 revenue grew by 11% vs. our expectation of 15% due to supply chain bottleneck and lower takeoff biosimilars' business in new geographies (covid-19 lockdown). EBITDA margins (22%) decreased by 400 bps on YoY due high R&D; expenses, frorex losses and other expenses.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

23 Oct 2020

399.65

0.30%

Biocon

Buy: Biocon Ltd.

Sharekhan

Q2FY2021 was a soft quarter for Biocon. Revenues from operations grew by 11% y-o-y to Rs 1,745 crore. Adjusted PAT rose by 10.3% y-o-y to Rs. 173.8 crore. Improving traction in existing biosimilars, likely pick up in Semglee, geographical expansion are the key growth drivers for Biologics segment. Biocon has retained its guidance for $1 billion in revenues from the biologics segment...

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.

Biocon Ltd.

23 Oct 2020

399.65

0.30%

Biocon

Buy: Biocon Ltd.

Target

ICICI Securities Limited

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.

Biocon Ltd.

23 Oct 2020

399.65

0.30%

Operational challenges impact performance

Neutral: Biocon Ltd.

Target

Motilal Oswal

Biocon Ltd. has an average target of 390.50 from 4 brokers.

Biocon Ltd.

28 Sep 2020, 12:00AM

399.65

0.30%

Pick of the Week:28 SEP 2020

Buy: Biocon Ltd.

Axis Direct

Biocon Ltd is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immune suppressants and anti-diabetic drugs.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

27 Jul 2020, 12:00AM

399.65

0.30%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

Biocon reported a muted set of numbers for Q1FY21 with revenues growing at 14% on annual comparison but EBIDTA contracted by~6% and PAT by 27% on back of rising costs of Biologics business and higher R&D; spends.

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.

Biocon Ltd.

25 Jul 2020

399.65

0.30%

Healthy recovery in Biologics; Improved demand scenario for Generics

Neutral: Biocon Ltd.

Target

Motilal Oswal

Capital investment and product development are on track for the Generics segment, additional We maintain our EPS estimates for FY21/FY22 and value BIOS at 30x (20% discount to its five-year avg.), arriving at TP of INR450. BIOS is well-placed to deliver a 39% earnings CAGR over FY2022, led by new launches / increased market share for existing products in the Biologics segment and superior performance from the Generics / Research Services segment. New contracts, led by Mylans efforts, would lead to better market share going BIOS is on track with regard to developing Insulin Aspart. Considering new launches and strong traction from existing products, we expect a 43% CAGR in revenue to INR40b over FY2022. An increase in the number of customers and better traction from existing customers are expected to drive a 12 13% CAGR in Research Services revenue over FY2022E. BIOS delivered 16% YoY growth in this segment, led by favorable demand for API.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

24 Jul 2020

399.65

0.30%

Biocon

Buy: Biocon Ltd.

Target

ICICI Securities Limited

Q1FY21 revenues grew 14% YoY to | 1671 crore (I-direct estimate: | 1651 crore) mainly due to 18.9% YoY growth in biosimilars to | 692 crore. The Generics segment grew 16.1% YoY to | 599 crore. Research services segment remained flat YoY at | 422 crore. EBITDA margins contracted 512 bps YoY to 24.7% (I-direct estimate: 22.2%) mainly due to lower gross margins and higher R&D; costs. EBITDA declined 5.5% YoY to | 413 crore against I-direct estimate of | 366 crore. Adjusted PAT declined 27.6% YoY to | 149 crore (I-direct estimate: | 127 crore). Delta vis--vis EBITDA was due...

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

12 Jun 2020

399.65

0.30%

Major milestone hit with USFDA approval for Insulin Glargine

Neutral: Biocon Ltd.

Target

Motilal Oswal

Insulin Glargine (Semglee) is Biocon-Mylans third biosimilar to be approved by the USFDA in a span of 24 months. Considering two competitors (Innovator- Sanofi; Biosimilar by Eli Lilly/Boehringer Ingelheim team; EL/BI) are already in the market and Biocon-Mylan are the third to get USFDA approval with other peers still under clinical phase, we expect Biocon (BIOS) to garner USD130m on an annualized basis from this opportunity, post commercialization in 2HFY21. BIOS recently received the USFDAs approval for its Insulin Glargine (biosimilar version Semglee) for both versions (vial and pen). Further, BIOS-Mylan has recently won a favorable ruling from the US Patent and Trial Board (USPTAB) in the patent litigation against Sanofi for 4 device patents for Lantus SoloSTAR. Moreover, in Mar20, the US district Court of New Jersey ruled that Sanofis 844 patent (product patent) was not infringed by Mylans Insulin Glargine product.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Is Biocon Ltd. worth buying?

733 Votes:

Buy 74.9%

Sell 16.37%

Hold 8.73%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf